Praxis PRAX insider option exercises and share sales for estate planning

Rhea-AI Filing Summary

Praxis Precision Medicines (PRAX) reported insider activity by its Principal Accounting Officer on a Form 4. On 11/20/2025, the officer exercised multiple stock options, acquiring Praxis common stock at exercise prices of $49.5, $83.85, $133.65, $43.37, $44.4, and $56.94 per share. The same day, the officer sold 11,455 shares at a weighted average price of $191.958 and 2,145 shares at a weighted average price of $192.711, in multiple transactions within narrow price ranges. After these transactions, the officer beneficially owned 10,441.656 shares of Praxis common stock directly. The filing notes that the transactions were effected for estate planning purposes, and several option grants referenced were already fully vested or continue to vest over time.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mastrocola Lauren

(Last) (First) (Middle)

C/O PRAXIS PRECISION MEDICINES, INC.

99 HIGH STREET, 30TH FLOOR

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Praxis Precision Medicines, Inc. [ PRAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Principal Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/20/2025		M		1,047	A	$49.5	11,488.656	D
Common Stock	11/20/2025		M		508	A	$83.85	11,996.656	D
Common Stock	11/20/2025		M		1,557	A	$133.65	13,553.656	D
Common Stock	11/20/2025		M		2,680	A	$43.37	16,233.656	D
Common Stock	11/20/2025		M		207	A	$44.4	16,440.656	D
Common Stock	11/20/2025		M		2,351	A	$44.4	18,791.656	D
Common Stock	11/20/2025		M		5,250	A	$56.94	24,041.656	D
Common Stock	11/20/2025		S		11,455	D	$191.958(1)	12,586.656	D
Common Stock	11/20/2025		S		2,145	D	$192.711(2)	10,441.656	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$49.5	11/20/2025		M			1,047	(3)	09/23/2029	Common Stock	1,047	$0.00	0	D
Stock Option (Right to Buy)	$83.85	11/20/2025		M			508	(4)	06/04/2030	Common Stock	508	$0.00	0	D
Stock Option (Right to Buy)	$133.65	11/20/2025		M			1,557	(5)	09/13/2030	Common Stock	1,557	$0.00	0	D
Stock Option (Right to Buy)	$43.37	11/20/2025		M			2,680	(6)	01/12/2034	Common Stock	2,680	$0.00	9,320	D
Stock Option (Right to Buy)	$44.4	11/20/2025		M			207	01/12/2023	01/12/2033	Common Stock	207	$0.00	0	D
Stock Option (Right to Buy)	$44.4	11/20/2025		M			2,351	(7)	01/12/2033	Common Stock	2,351	$0.00	981	D
Stock Option (Right to Buy)	$56.94	11/20/2025		M			5,250	(8)	07/29/2034	Common Stock	5,250	$0.00	11,376	D

Explanation of Responses:

1. The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $191.500 to $192.432. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

2. The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $192.552 to $193.109. The Reporting Person undertakes to provide upon request from the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.

3. This option was fully vested as of January 1, 2023.

4. This option was fully vested as of May 28, 2024.

5. This option was fully vested as of September 8, 2024.

6. The shares underlying this stock option vested as to 50% on January 12, 2024 and the remaining 50% vesting over a four-year period, with 25% of such shares vesting on January 12, 2025 and the remaining vesting in substantially equal monthly installments over the following 36 months, subject to the Reporting Person's continued service through each vesting date.

7. The shares underlying this stock option vested as to 25% on January 12, 2024 and the remaining shares vest in substantially equal monthly installments over the following 36 months, subject to the Reporting Person's continued service through each vesting date.

8. The shares underlying this stock option vested as to 7/48ths on July 29, 2024 and the remaining shares vest in substantially equal monthly installments over the following 41 months, subject to the Reporting Person's continued service through each vesting date.

Remarks:

The transactions reported in this Form 4 were effected for estate planning purposes.

	/s/ Alex Nemiroff, as Attorney-in-Fact	11/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Praxis Precision Medicines (PRAX) disclose?

Praxis Precision Medicines disclosed that its Principal Accounting Officer filed a Form 4 showing multiple stock option exercises into common stock and same-day sales of a portion of those shares on 11/20/2025.

How many Praxis (PRAX) shares were sold in the reported Form 4?

The officer sold 11,455 Praxis common shares at a weighted average price of $191.958 and 2,145 shares at a weighted average price of $192.711, each in multiple transactions within stated price ranges.

What is the insider’s remaining Praxis (PRAX) share ownership after the transactions?

Following the reported option exercises and sales, the officer beneficially owned 10,441.656 shares of Praxis common stock, held directly.

At what prices were the Praxis (PRAX) stock options exercised?

The options were exercised into Praxis common stock at exercise prices of $49.5, $83.85, $133.65, $43.37, $44.4, and $56.94 per share, as listed in the Form 4 tables.

What reason was given for the Praxis insider transactions?

The remarks state that the transactions reported were effected for estate planning purposes, indicating a personal financial-planning motive for the option exercises and share sales.

Were the Praxis (PRAX) stock options fully vested at the time of exercise?

Several options were disclosed as fully vested as of specific dates (such as January 1, 2023, May 28, 2024, and September 8, 2024), while others vest in scheduled installments over future months and years.